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Cationic amphiphilic drugs (CADs) comprise a wide variety of different substance classes such as 
antidepressants, antipsychotics, and antiarrhythmics. It is well recognized that CADs accumulate 
in certain intracellular compartments leading to specific morphological changes of cells. So far, no 
adequate technique exists allowing for ultrastructural analysis of CAD in intact cells. Azidobupramine, 
a recently described multifunctional antidepressant analogue, allows for the first time to perform 
high-resolution studies of CADs on distribution pattern and morphological changes in intact cells. 
We showed here that the intracellular distribution pattern of azidobupramine strongly depends on 
drug concentration and exposure time. The mitochondrial compartment (mDsRed) and the late endo-
lysosomal compartment (CD63-GFP) were the preferred localization sites at low to intermediate 
concentrations (i.e. 1 μM, 5 μM). In contrast, the autophagosomal compartment (LC3-GFP) can only 
be reached at high concentrations (10 μM) and long exposure times (72 hrs). At the morphological 
level, LC3-clustering became only prominent at high concentrations (10 μM), while changes in CD63 
pattern already occurred at intermediate concentrations (5 μM). To our knowledge, this is the first study 
that establishes a link between intracellular CAD distribution pattern and morphological changes. 
Therewith, our results allow for gaining deeper understanding of intracellular effects of CADs.
The clinical efficacy of small molecules results from a complex interplay of various pharmacodynamic and phar-
macokinetic processes and appears to be significantly influenced not only by regional (tissue specific) but also by 
(sub-)regional (intracellular) distribution patterns1. Distribution patterns of small molecules, in turn, are deter-
mined by their physicochemical properties2. While a plethora of information is available on how small molecules 
accumulate in tissues and in cells, significantly less is known about their exact subcellular localization3,4.
Cationic amphiphilic drugs (CADs) are well known for their potential to accumulate intracellularly in certain 
compartments. This drug family comprises a wide variety of substance classes such as antidepressants, neurolep-
tics, cardiac antiarrhythmics, and tranquilizers5. Common to all these molecules is their amphiphilic character 
that is brought about by hydrophobic head structures and hydrophilic side chains equipped with amines6. So far, 
the most common method for analysis of the intracellular accumulation pattern of CADs was the combination 
of radiolabeling of small molecules and differential centrifugation. It has been shown repeatedly that CADs, 
and in particular antidepressants, accumulate in compartments like synaptosomes, microsomes, mitochon-
dria, and nuclei7–10. The major drawback of the use of radiolabeled compounds for intracellular CAD distribu-
tion assessment is the risk of accidental redistribution of the radioactive tracer into neighbor compartments. 
To overcome these obstacle, intrinsically fluorescent small molecules were tested regarding their suitability for 
monitoring changes in intracellular distribution pattern. Unfortunately, only a limited selection of intrinsically 
fluorescent CADs is available to date: amiodarone11–16, chloroquine16–19, clofazimine20, and quiancerine14,21–23 
are the most frequently reported molecules. All four substances enrich in vesicular structures belonging to the 
endo-lysosome-secretory granule complex. However, low to moderate detection sensitivity and resolution made 
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the quantification difficult. Further methodological alternatives for monitoring intracellular CAD distribution 
are Raman scattering microscopy and second ion mass spectrometry. In accordance with the findings obtained 
with intrinsically fluorescent molecules, Raman scattering microscopy revealed a predominantly intravesicular 
localization of CADs such as chloroquine and clofazimine17,20. Ion mass spectrometry, on the other hand, offers 
the potential of very high resolution and sensitivity but has so far not been employed in investigating intracellular 
distribution pattern of CADs. Although both of these methods represent promising methodological options, they 
come along with major technical challenges limiting their applicability24–27.
The aim of this study was to re-evaluate the intracellular distribution pattern of CADs using the recently syn-
thetized and characterized CAD azidobupramine, a chemically modified antidepressant harnessing the power of 
modern medicinal chemistry to overcome above mentioned limitations28: azidobupramine carries an azide-group 
amenable for photoaffinity labelling (PAL) and an alkyne-group enabling chemical bonding of fluorescent tags 
by click-chemistry (CuAAC). These modifications allow for UV-induced immobilization of this CAD in living 
cells and subsequent for labeling with fluorophores without hampering subcellular structures. Here, we put a par-
ticular focus on the analysis of subcellular compartments which were previously reported to accumulate CADs. 
To achieve that, we employed cells stably expressing markers specifically targeting mitochondria, late endosomes 
and autophagosomes.
Results
Quantification of intracellular azidobupramine. First, we investigated the intracellular accumulation 
of azidobupramine (Figs 1 and 2A). HeLa cells were treated with azidobupramine at three different concentrations 
(1 μ M, 5 μ M, and 10 μ M) over four different periods of time (40 min, 24 hrs, 48 hrs, and 72 hrs). The fluorescent 
signal was recorded after azidobupramine was immobilized on its target site by UV-crosslinking and the azidobu-
pramine-target complexes were labelled with fluorescent dyes by click-chemistry (S-Fig. 1). Control cells were 
treated with equivalent volumes of the solvent DMSO. We observed that the fluorescence intensity increased both 
with time and increasing concentrations of azidobupramine indicating that the fluorescence signal measured was 
specific for azidobupramine (Fig. 2A). The Stokes Shift of all dyes used in the study were in the normal range of 
the Alexa dyes: excitation and emission could be separated clearly with our setup. Possible quenching effects at the 
highest dye-concentration could not be excluded ultimately but would render the observed effect even stronger 
than weakening it. Furthermore, we detected almost no fluorescence in cells treated with the control substances 
DMSO or clomipramine (Fig. 2B). The latter is a clinically active antidepressant which, in contrast to azidobu-
pramine, is not chemically modified and hence does neither harbor an azido-group for UV-crosslinking nor an 
alkyne-group for click chemistry.
Localization of intracellular azidobupramine signal. Next, we tested the intracellular distribution pat-
tern of azidobupramine. We investigated the colocalization of azidobupramine with cellular organelle markers 
that have been described in context with a number of CADs and in particular with antidepressants7–10. For this, 
the intensity correlation quotient (ICQ) was calculated29. The ICQ can adopt values from − 0.5 to + 0.5: − 0.5 is 
indicative of complete anti-localization of the signal measured, + 0.5 indicative of complete co-localization, and 
0.0 stands for random colocalization (S-Fig. 2)29. Three different cellular markers were employed: (a) the green 
fluorescent protein (GFP)-coupled tetraspanin CD63 (CD63-GFP) indicative of the late endosome-lysosomal 
compartment, (b) the GFP coupled microtubule-associated protein 1 A/1B-light chain 3 (LC3-GFP) indicative of 
the autophagosomal compartment, and (c) the red fluorescence protein expressed in the mitochondria (mDsRed) 
indicative of the mitochondrial compartment.
First, compartment specific distribution patterns of azidobupramine were analyzed in relation to the three 
predefined compartments: the mitochondrial compartment (marker: mDsRed), the endo-lysosomal compart-
ment (marker: CD63-GFP), and the autophagosomal compartment (marker: LC3-GFP) (Fig. 3A–C). The mito-
chondrial compartment was the first place of accumulation, independent of its applied concentration (Figs 4 and 
3A; S-Fig. 5). Over time, however, the respective ICQs evolved differently not only in respect to the mitochon-
drial compartment but also to the endo-lysosomal (CD63-GFP) and autophagosomal (LC3-GFP) compartments. 
While the co-localization of mDsRed and azidobupramine remained stable at high concentrations (i.e. 5 μ M 
and 10 μ M), a significant decrease in ICQs was detected at 1 μ M over time. The endo-lysosomal compartment, 
however, became significantly targeted between 40 minutes and 24 hours. Overall, our analyses revealed that 
endo-lysosomal vesicles positive for CD63-GFP are the most preferred places of azidobupramine accumulation 
(Figs 5 and 3B, S-Fig. 6). The most pronounced accumulation of azidobupramine within CD63 positive vesicles 
was found in cells that were stimulated with 10 μ M azidobupramine over at least 48 hours (Figs 5 and 3B, S-Fig. 6). 
In contrast to the CD63 positive compartment, the LC3 compartment was targeted only at the highest concentra-
tion of azidobupramine (i.e. 10 μ M) - most intensely after 72 hours (Figs 6 and 3C, S-Fig. 7).
Second, the intracellular distribution patterns of azidobupramine were analyzed in relation to the azidobu-
pramine concentration applied (Fig. 7A–C). At 1 μ M, the strongest colocalization was observed in the mitochon-
drial compartment and the CD63-positive endo-lysosomal compartment, while the LC3-positive autophagosomal 
compartment played only a subordinate role (Fig. 7A). The same applied to the 5 μ M condition (Fig. 7B). At the 
10 μ M condition, however, the increasing colocalization of azidobupramine in the LC3-positive autophagosomal 
compartment became more apparent than in the mitochondrial and CD63-positive endo-lysosomal compart-
ment (Fig. 7C).
When ICQs (Figs 3A–C and 7A-C) were put in relation to differences in intracellular accumulation of azi-
dobupramine (Figs 1 and 2A), the extent of concentration and time-dependent differences became even more 
obvious. While azidobupramine signals were only low to moderate at 1 μ M and 5 μ M, concentrations of 10 μ M 
resulted in an unexpected increase in signal intensity, which might have caused the rise in the ICQs of azidobu-
pramine in the LC3-positive autophagosomal compartment. Further evaluation of the physiological implication 
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of the increase in signal intensity and site specific colocalization, however, was not part of this study and should 
be the matter of future analyses.
Analysis of LC3 and CD63 marker protein patterns. To put our findings in a broader context, we com-
pared the effects of azidobupramine and the clinically active antidepressant clomipramine on CD63 vesicularity 
and LC3 clustering.
CD63 vesicularity was equal to an increase of hollowness of CD63 positive vesicles (S-Fig. 3). The correspond-
ing measure, i.e. the vesicularity index (VI), can adopt values between zero and one. The larger the VI, the more 
pronounced is the hollowness of CD63 positive vesicles (Fig. 8A,B).
At concentrations of 1 μ M, azidobupramine and clomipramine exerted barely any effect on the VI of CD63 
positive vesicles. However, a significant increase in VI was detected upon treatment with azidobupramine and 
clomipramine at 5 μ M and 10 μ M if the incubation time exceeded 40 minutes (Fig. 8A,B). It appears that 10 μ M 
clomipramine stimulated the expansion of CD63 positive vesicles more intensely than 10 μ M azidobupramine.
Lipidation and clustering of the LC3 protein has been frequently associated with CAD and antidepressant 
effects30–32. Therefore we compared the effects of DMSO, azidobupramine and clomipramine on LC3 clustering 
represented by the clustering index (CI). The CI is a measure indicative of the degree of signal condensation – 
high CI values is indicative to highly condensed dots and low CIs for a dispersed signal (S-Fig. 4). After DMSO 
treatment, we found the LC3 protein to be homogeneously dispersed throughout the cell which was reflected 
Figure 1. Intracellular accumulation of azidobupramine. For the detection of intracellular azidobupramine 
accumulation (white (false colored image)) Hela cells were exposed to different concentrations of 
azidobupramine (1 μ M, 5 μ M, and 10 μ M) and different time periods (40 min, 24 hrs, 48 hrs, and 72 hrs) 
followed by an immobilization step (UV-light), and labeling of azidobupramine with fluorescent dyes by click-
reaction; each picture represents a z-stag of one representative cell that was also the basis for the quantification; 
DMSO concentration was set to 0.1% in in all conditions.
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by CI values around zero (Fig. 8C,D). However, LC3-clustering occurred upon treatment with ≥ 5 μ M azidobu-
pramine or clomipramine. The highest CIs were achieved upon treatment with 10 μ M azidobupramine or clomi-
pramine for longer than 40 minutes (Fig. 8C,D).
Discussion
Using azidobupramine as model substance, we demonstrate here for the first time that the vesicular accumula-
tion of CADs is accompanied by an expansion of CD63-positive vesicles33,34. Furthermore, we show for the first 
time a time- and concentration-dependent intracellular accumulation of the CAD azidobupramine (Figs 1 and 
2A) thereby further corroborating its suitability as a multifunctional tool for monitoring the intracellular fate 
of CADs. The substance concentrations chosen in the actual study were based on estimations of steady state 
concentrations of antidepressant in the central nervous system35,36, consensus guidelines for Therapeutic Drug 
Monitoring (TDM) in psychiatry37, and practiced reality. These considerations let us to include concentrations 
from 1 μ M (therapeutic dose) to 10 μ M (concentrations used in the cell biology and biochemical assays) enabling 
us to describe cellular effects at both non-toxic as well as at most likely toxic conditions.
Concentrations up to 5 μ M azidobupramine led to an approximately linear increase in intracellular substance 
load over the total exposure time of 72 hours. A concentration of 10 μ M, however, produced a disproportion-
ate increase in intracellular substance load at later time points. A possible explanation for this phenomenon 
could be that limits of distinct saturable biological processes might be exceeded: Transport molecules such as the 
outward-facing P-glycoprotein (ABCB1), or other cellular detoxification processes are possible mechanisms that 
might be overrun at high CAD concentrations. Finally, we show that the effects of azidobupramine and the clini-
cally active antidepressant clomipramine on CD63 vesicularity and LC3 clustering resemble each other underpin-
ning azidobupramine as relevant tool to analyze intracellular distribution pattern of cationic amphiphilic drugs.
According to our findings, the mitochondrial compartment is one of the first intracellular target structures 
of azidobupramine (Fig. 7). This result is in accordance with findings of studies having used another analysis 
technique, namely a combination of radioactively labelled CADs together with differential centrifugation7–10. 
Theoretical considerations towards consequences of physicochemical properties of CADs on subcellular target 
structures resulted in hypotheses regarding their intracellular distribution pattern. According to these hypotheses 
and to measurements using radioactively labelled substances, CADs accumulate within the cytoplasm by a factor 
of 5–10 in comparison to the extracellular environment and further by a factor of 20–30 within the mitochon-
dria in comparison to the cytoplasm. Depending on the test concentrations used, this led to the accumulation 
of CADs within mitochondria up to the millimolar range38. In addition to the electrochemical (Δ Ψ ) and pH 
gradients across outer membranes, also compartment-specific lipid compositions are held responsible for the 
mitochondrial accumulation39. In fact, twenty percent of the lipids of the inner membrane of the mitochondria 
are phospholipids known as facilitators of CAD translocation39–41.
Figure 2. Quantification of intracellular azidobupramine. Quantification of the azidobupramine specific 
intracellular fluorescence signal at Hela cells treated as exemplified in Fig. 1: group analysis revealed higher 
cellular fluorescence under AZB 10 μ M as compared to DMSO at all measurement times, as compared to 
AZB 1 μ M after 24 hours, and as compared to AZB 5 μ M after 48 hours; throughout the assessment, cellular 
fluorescence intensity became higher only under AZB 10 μ M concentration (A). Control experiments for 
unspecific fluorescent signal: the fluorescence signal was measured after Hela cells were treated with 10 μ M  
azidobupramine, clomipramine or DMSO over 72 hrs after UV-crosslinking and different click-reaction 
conditions with and without the copper-ion indispensable for click-reaction; One-way ANOVA revealed main 
effect of group (F(4, 10) = 44.26, p ≤ .001), with post-hoc analysis showing significant differences between AZB 
click with copper as compared to other variables at significance levels all at p ≤ .001 (B). *p < 0.05; **p < 0.01; 
***p < 0.001; each data point represents the mean ( ± SEM) of three independent experiments comprising the 
integration and averaging of the fluorescent signal of 10 distinct cells; for more detailed statistical data please be 
referred to the supplementary material legend extension of Fig. 2.
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According to literature, CADs initially become accumulated and protonated within the intermembrane space 
driven by Δ Ψ , followed by a phospholipid mediated translocation step to the matrix and partial deprotonation 
within the matrix due to higher pH-values – the difference in pH values between intermembrane space and 
matrix is estimated to be 0.541. This essentially means that once CADs become trapped within the mitochondria 
they are hindered from getting out of it. In our experiments, azidobupramine appeared to stably reside in the 
mitochondrial compartment at concentrations higher than 5 μ M. At concentrations of 1 μ M (Fig. 3A). However, 
azidobupramine showed strong colocalization with the mitochondrial compartment only at 40 minutes. While 
it is not possible to make statements on the actual concentrations of azidobupramine within the mitochondrial 
compartment, we conclude from our findings that a minimal amount of azidobupramine is necessary to keep 
azidobupramine constantly trapped within the mitochondria. In further studies, it remains to be clarified for each 
CAD whether and to what extent the mitochondrial accumulation is relevant for its clinical efficacy even though 
strong evidence exists to support the clinical relevance42,43.
In the case of azidobupramine, it was not the mitochondrial compartment, but certain vesicular structures 
that significantly account for the accumulation observed, especially at higher concentrations (Fig. 3A–C). In 
particular, vesicles that were positive for the CD63 marker were identified to be the most intensely targeted 
compartment (Fig. 3B). The CD63 surface-associated marker protein is involved in tightly regulated endocy-
totic and exocytotic processes, but also in other multiple intracellular cargo and trafficking activities. Of note, 
CD63-positive exosomes are also responsible for mRNA shuttling44. In a series of studies it has been shown 
that the CAD amiodarone induces an expansion of CD63-positive vesicles which were subsequently categorized 
as perinuclear hybrid-organelles sharing lysosomal and late-endosomal characteristics14. Similar effects on the 
enlargement of CD63-positive vesicles were also described for other CADs such as procainamide45. The study at 
hand, however, is the first that proves the colocalization of a CAD with CD63-positive vesicles and that monitors 
the CAD accumulation within this compartment over time and at different concentrations.
The origin of the CD63-positive vesicles has been discussed quite diversely. While some studies propose that 
CD63-positive vesicles originate from the trans-Golgi apparatus, others suggest that mitochondria are involved 
in their formation45. CAD-induced changes of the CD63-associated endocytotic and exocytotic pathways may 
account for the expansion and accumulation of CD63-positive vesicles overloaded with CADs.
The LC3 lipoprotein is strongly linked to autophagy and autophagy-associated processes46. Furthermore, it is 
well known that CADs modulate autophagy and autophagy-associated processes and intervene with LC3 and LC3 
metabolism14. We show here that colocalization of LC3 and azidobupramine occurred only at concentrations of 
10 μ M and exposure times of at least 24 hours (Fig. 3C). It is not clear at this point whether this colocalization is of 
physiological relevance or a mere reflection of the massive intracellular overload of azidobupramine.
In summary, this study shows that azidobupramine is a substance that allows for studying intracellular CAD 
distribution pattern. We illustrate that the subcellular localization of azidobupramine can be traced in a way that 
allows temporal and spatial resolution. Furthermore, we demonstrate that the distribution of azidobupramine 
follows a characteristic pattern that is strongly dependent on the substance concentrations and exposure times. 
After reaching the mitochondrial compartment, azidobupramine, in particular at higher concentrations, seemed 
Figure 3. Analysis of compartment specific distribution pattern of azidobupramine related to 
concentrations used. Colocalization of azidobupramine with the mitochondrial compartment was analyzed with 
two-way ANOVA with repeated measures: after 24 hours, the intensity correlation quotient was lower under 
AZB 1 μ M in comparison to AZB 5 μ M as well as to AZB 10 μ M; throughout the assessment, time-related 
changes were observed only under AZB 1 μ M (A). Colocalization of azidobupramine with the endo-lysosomal 
compartment was analyzed with two-way ANOVA with repeated measures: group analyses revealed at both 
measurement times 24 hours and 72 hours significant differences between AZB1 μ M as compared with AZB5 μ 
M as well as with AZB10 μ M (B). Colocalization of azidobupramine with the autophagosomal compartment was 
analyzed with two-way ANOVA with repeated measures: group differences were observed between AZB 1 μ M 
and AZB 10 μ M at all measurement times; moreover, intensity correlation quotient for AZB 1 μ M was lower 
than AZB 5 μ M at 40 minutes and for AZB 5 μ M was lower than AZB 10 μ M at both 24 hours and 72 hours 
(C). *p < 0.05; **p < 0.01; ***p < 0.001; each data point represents the mean ( ± SEM) of three independent 
experiments averaging the signal of 10 distinct cells; for more detailed statistical data please be referred to the 
supplementary material legend extension of Fig. 3.
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to be (re-)distributed to CD-63 positive vesicles and LC3 compartments (Fig. 7C). It is important for further 
studies that a minimum amount of azidobupramine is necessary to initiate accumulation. While only weak but 
significant signals could be monitored after cells were treated at 1 μ M azidobupramine, strong accumulation was 
observed only after the treatment at 10 μ M.
Future studies have to be conducted to explore how the herein observed intracellular CAD distribution pattern 
is related to CAD function. The findings here help to further elucidate the intracellular functions of CADs and in 
particular of antidepressants. Such knowledge is essential since other mechanisms of action than enhancement 
of monoaminergic neurotransmission may play an important role in conveying beneficial clinical effects47–54.
Methods
Chemical Synthesis. Azidobupramine was synthesized as described recently28.
Materials and Chemicals. The following materials were purchased: Minimal Essential Media (MEM), 
FreeStyleTM 293 Expression medium, Fetal Bovine Serum (FBS), antibiotic-antimycotic, L-glutamine, and 
non-essential amino acids, Alexa-Fluor-488-Azide, Prolong Gold Antifade, WGA Alexa-Fluor-647-Azide con-
jugate (Life Technologies, CA, USA); clomipramine, Hank’s Balanced Salt Solution (HBSS), gelatin (SigmaAldrich, 
MO, USA); PFA 37% (Merck, Darmstadt, Germany); BTTAA was kindly provided by S. Sieber (Technical 
University Munich, IAS, CIPSM, Department of Chemistry, Garching, Germany).
Cell culture. HeLa cells stably expressing EGFP-CD63, EGFP-LC3, and mDsRed were kindly pro-
vided by A.M. Tolkovski (Department of Biochemistry, University of Cambridge, Cambridge, UK)55; for 
Figure 4. Colocalization of azidobupramine with the mitochondrial compartment. Hela cells stably 
expressing mDsRed a marker protein (yellow) for the mitochondrial compartment were exposed to 
azidobupramine at 10 μ M (Alexa Fluor 488, green) for varying time periods (40 min, 24 hrs, 48 hrs, and 72 hrs) 
followed by UV-light crosslinking and click-chemistry; the colocalization of azidobupramine with mDsRed was 
most prominently detectable after 40 minutes and 24 hours and less obvious at 48 hours and 72 hours;  
DMSO concentration was set to 0.1% in in all conditions.
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immunohistochemical analysis, cells were cultivated adherently (90% MEM, 10% FBS, 2 mM L-glutamine, 
non-essential amino acids).
Stimulation experiments. For stimulation experiments, HeLa cells were cultivated on glass plates pre-
coated with 0.1% gelatin, inoculated at a cell density of approximately 2500 cells/cm2. After a resting period of 
12 hours, cells were kept in cultivation over another 72 hours without changing the medium. Cells were stimu-
lated over different time periods (72 hrs, 48 hrs, 24 hrs, and 40 min) and at different concentrations (10 μ M, 5 μ M, 
and 1 μ M) of clomipramine or azidobupramine. The stock solutions for clomipramine and azidobupramine were 
prepared in DMSO at a 1000 fold higher concentrations than necessary for the stimulation (10 mM, 5 mM, and 
1 mM); the dilution guarantees that the final DMSO concentration does not exceed 0.1%. For control conditions, 
only the vehicle DMSO was used.
Histochemical staining. For histochemical staining, cells were exposed to UV-light using the Dual 
Transilluminator from Stratagene (5 × 8 Watt at 312 nm, La Jolla, CA, USA) for 60 seconds. Then, paraformal-
dehyde (PFA) was added to the medium to a final concentration of 4% over 30 minutes at cell culture conditions 
(37 °C, 5% CO2). This was followed by three washing steps with HBSS, a cell membrane staining process (1 μ g/ml 
WGA647 diluted in HBSS, 7’, RT), and an additional fixation step with 4% PFA (30′ , RT). To prepare cells for the 
copper mediated click reaction, cells were washed three times with PBS (RT) followed by the actual CuAAC reac-
tion conducted for 30 minutes at RT in PBS supplemented with 25 μ M fluorophore-azide, 2.5 mM ascorbic acid, 
250 μ M CuSO4, and 500 μ M bis[(tertbutyltriazoyl)methyl]-[(2-carboxymethyltriazoyl)methyl]amine (BTTAA) 
(S-Fig. 1). The fluorescent dyes used were 5-TAMRA-Azide (baseClick, Neuried, Germany) for HeLa cells stably 
expressing EGFP-CD63 or EGFP-LC3, and Alexa-Fluor-488-Azide for HeLa cells positive for mDsRed (S-Fig. 1); 
the fluorophores Alexa-Fluor-647, Alexa-Fluor-488-Azide, and 5-TAMRA-Azide were used because of their 
Figure 5. Colocalization of azidobupramine with the endo-lysosomal compartment. Hela cells stably 
expressing the endo-lysosomal marker CD63-GFP (green) were exposed to azidobupramine at 10 μ M  
(5-TAMRA, yellow) and varying time periods (40 min, 24 hrs, 48 hrs, and 72 hrs) followed by UV-light 
crosslinking and click-chemistry; the colocalization of azidobupramine and CD63 becomes increasingly 
stronger over time; DMSO concentration was set to 0.1% in in all conditions.
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known stability in a broad range of pH values. After three further washing steps with PBS, the coverslips were 
immersed into water before they were embedded in ProLong Gold Antifade. The specimens were kept at dark 
and cold (4 °C) until analysis.
Microscopy. Microscopic images were acquired by the commercially available Zeiss Cell Observer SD with a 
Yokogawa spinning disk unit. To account for different experimental setups (i.e. quantification of azidobupramine, 
determination of CD63-vesicularity, and measurement of LC3-clustering), laser powers and exposure settings 
were adjusted individually and kept constant throughout the whole measurement allowing comparability. For the 
analysis of LC3- and CD63-topology and for colocalization measurements, single slices through the lower part 
of the cells with an optical section depth of 270 nm were recorded. For uptake measurements, z-stacks from the 
bottom to the top of the cells were acquired with a z-spacing of 270 nm.
Image analysis. For data analysis and visualization, Fiji56 and Imaris (Bitplane AG, Zurich, Switzerland) 
were employed. For uptake measurements, background fluorescence was subtracted at all slices of the z-stack. 
Then, a threshold was applied in order to quantify only the internalized AZB signal. Finally, the intracellular AZB 
signal was summed up over all slices. The result was defined as the amount of internalized AZB. For colocaliza-
tion measurements and analysis of LC3- and CD63-topology, special algorithms were applied that are described 
in detail in the supplementary material (S-Figs 2, 3 and 4). Briefly, for colocalization analysis, Li’s ICQ method 
was applied29 (S-Fig. 2). It compares pixel-wise, after normalization of the image histograms, whether the inten-
sities of the two investigated images change synchronously (indicating colocalization), randomly (indicating 
Figure 6. Colocalization of azidobupramine with the autophagosomal compartment. Hela cells stably 
expressing the autophagosomal marker LC3-GFP (green) were exposed to azidobupramine at 10 μ M  
(5-TAMRA, yellow) and varying time periods (40 min, 24 hrs, 48 hrs, and 72 hrs) followed by UV-light 
crosslinking and click-chemistry; after 40 minutes at 10 μ M azidobupramine hardly any LC3-clustering 
and colocalization of LC3 and azidobupramine can be observed; over time the LC3 clustering and the LC3/
azidobupramine-colocalization becomes more prominent; DMSO concentration was set to 0.1% in in all 
conditions.
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Figure 7. Analysis of concentration related effects on compartment specific distribution pattern.  
(A) Preferred colocalization of azidobupramine with different compartments at 1 μM: group analyses showed 
significant differences between both CD63 and mDsRED as compared to LC3 at all measurement times; 
moreover, the intensity correlation quotient for CD63 was lower than for mDsRED at 40 minutes (A). Preferred 
colocalization of azidobupramine with different compartments at 5 μM: the intensity correlation quotient was 
lower for LC3 as compared to both CD63 and mDsRED at all measurement times; moreover, at 40 minutes 
intensity correlation quotient for CD63 was lower than for mDsRED; throughout the experiment, time-related 
changes were observed for CD63 between 40 minutes and 24 hours as well as between 40 minutes and 72 hours 
(p = 0.011) (B). Preferred colocalization of azidobupramine with different compartments at 10 μM: group 
differences were observed between both mDsRED and CD63 as compared to LC3 at three first measurement 
times; throughout the protocol, time-related changes were observed for LC3 between 40 minutes and 24 hours 
(C). *p < 0.05; **p < 0.01; ***p < 0.001; each data point represents the mean (± SEM) of three independent 
experiments averaging the signal of 10 distinct cells; for more detailed statistical data please be referred to the 
supplementary material legend extension of Fig. 7.
Figure 8. Comparison of the effects of azidobupramine and clomipramine on CD63-vesicularity and 
LC3-clustering. Analysis of azidobupramine’s effects on CD63-vesicularity: group analyses showed significant 
differences between DMSO and all AZB concentrations at 24 hours; moreover, at 24 hours AZB 1 μ M showed a 
lower vesicularity index than both AZB 5 μ M and AZB 10 μ M; at 48 hours, both AZB 5 μ M and AZB 10 μ M  
produced a higher vesicularity index than both DMSO and AZB 1 μ M; at 72 hours, DMSO showed a lower 
vesicularity index than both AZB 10 μ M and AZB 5 μ M, additionally vesicularity index for AZB 5 μ M was 
higher than AZB 1 μ M (A). Analysis of clomipramine effects on CD63-vesicularity: group analyses showed higher 
vesicularity for both CMI 10 μ M and CMI 5 μ M as compared to both DMSO and CMI 1 μ M after 24 hours; 
moreover CMI 5 μ M and CMI 10 μ M differed in their vesicularity index at both 24 hrs and 48 hrs as well as 
CMI 1 μ M was higher than DMSO at 48 hrs (B). Analysis of azidobupramine effects on LC3-clustering: group 
analyses showed a higher clustering index for AZB 10 μ M as compared to AZB 5 μ M, AZB 1 μ M, and DMSO 
after 24 hours (C). Analysis of clomipramine effects on LC3-clustering: group analyses showed higher clustering 
index for CMI10 μ M as compared to CMI5 μ M, CMI1 μ M, and DMSO after 24 h; moreover, CMI5 μ M had 
higher clustering index than CMI1 μ M at 24 h as well as DMSO both at 40’ and 24 h (C). *p < 0.05; **p < 0.01; 
***p < 0.001; each data point represents the average of signal integration of 10 cells, each performed in 
triplicates; for more detailed statistical data please be referred to the supplementary material legend extension of 
Fig. 8.
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random colocalization) or asynchronously (indicating anticolocalization). This analysis yields the colocalization 
coefficient, ranging from − 0.5 (complete anticolocalization) over 0 (random colocalization) to + 0.5 (complete 
colocalization)29. For the analysis of CD63, we defined the term solidity of the CD63-signals as explained in the 
supplementary material (S-Fig. 3). The term solidity was defined as quotient between the area of the fluorescence 
signal and that area of the convex hull. The lower this value is, the less solid and the hollower (i.e. vesicle-like) is 
the signal. Vesicularity then is defined as one minus solidity thus ranging from zero to one. Finally, for clustering 
analysis of LC3, the total amount of the LC3-signal was quantified in a first step (S-Fig. 4). Then, we defined a 
threshold in such a way that only the LC3-signal localized in clusters was quantified. The ratio of the LC3-signal 
in clusters divided by the total LC3-signal was defined as the cluster index, ranging from zero to one.
Statistical analyses. Statistical analyses were performed with SPSS software version 18.0 (SPSS Inc., Chicago 
IL). Analysis of the intracellular azidobupramine signal by means of fluorescence microscopy (Fig. 2A), analysis 
of colocalisation of azidobupramine with the mitochondria compartment or vesicular compartment positive for 
CD-63 and LC3 (Figs 6A–C and 7A–C), analysis of the CD-63 vesicularity index (Fig. 8A,B), and analysis of the LC3 
clustering index (Fig. 8C,D) were calculated with two-way ANOVAs with repeated measures. In case of violation of 
the assumption of sphericity, Greenhouse-Geisser corrections were applied. Analysis of the control experiments for 
the fluorescence signal (Fig. 2B) was performed with one-way ANOVA. Multiple comparisons were Bonferroni cor-
rected. All data are shown as mean ± standard error of measurement (SEM). The significance level was set at p ≤ .05.
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